Penumbra (PEN) Cash from Investing Activities Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -41.67% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -472.46% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -16.93% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -111.03% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -40.94% |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | -69.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.39% |
| Dec 31, 2025 | -204.16% |
| Sep 30, 2025 | -165.15% |
| Jun 30, 2025 | -40.17% |
| Mar 31, 2025 | -26.66% |
| Dec 31, 2024 | -101.50% |
| Sep 30, 2024 | 39.54% |
| Jun 30, 2024 | 9.38% |
| Mar 31, 2024 | 81.20% |
| Dec 31, 2023 | 63.55% |
| Sep 30, 2023 | 3.51% |
| Jun 30, 2023 | 50.36% |
| Mar 31, 2023 | 2.19% |
| Dec 31, 2022 | 30.01% |
| Sep 30, 2022 | -11.84% |
| Jun 30, 2022 | 49.88% |
| Mar 31, 2022 | -20.99% |
| Dec 31, 2021 | -28.85% |
| Sep 30, 2021 | -34.14% |
| Jun 30, 2021 | 27.12% |
| Mar 31, 2021 | 50.56% |
| Dec 31, 2020 | 14.56% |
| Sep 30, 2020 | -27.54% |
| Jun 30, 2020 | -25.70% |
| Mar 31, 2020 | 44.32% |
| Dec 31, 2019 | -131.43% |
| Sep 30, 2019 | 78.99% |
| Jun 30, 2019 | -126.54% |
| Mar 31, 2019 | 170.81% |
| Dec 31, 2018 | 27.54% |
| Sep 30, 2018 | -143.28% |
| Jun 30, 2018 | -30.06% |
| Mar 31, 2018 | -31.81% |
| Dec 31, 2017 | -179.04% |